Day 4 (Presidential III) #ESMO26 highlights:
1. ARTEMIS-011: Risvutatug rezetecan (B7-H3 ADC) in osteosarcoma
2. MOIO: ⬇️ frequency IO in responders
3. TroFuse-005: Sac-TMT in ndometrial Ca
4. KEYNOTE-C93: Pembro mono in 1L dMMR Endometrial Ca
#OncTwitter @myESMO
1/5
263 浏览 · 3 赞 · 5 转发 · 4 回复
De-escalating IO drugs (MOIO trial): Interim pharmacokinetic and immunomonitoring analysis
https://esmocongress.esmo.org- Oncology Brothers@OncBrothers
4. KEYNOTE-C93: PhIII, pembro mono vs carbo/paclitaxel in 1L dMMR advanced/recurrent endometrial ca - mPFS 38.2 vs 8.4 mo (HR 0.57) - G≥3 TRAEs 18.1% vs 50.7% - DoR NR vs 10.2 mo - OS immature. IO/ICI regardless of aite, in dMMR, this remains the preferred backbone. 5/5
- Oncology Brothers@OncBrothers
3. TroFuse-005: PhIII, sacituzumab tirumotecan (TROP2 ADC) vs dox/paclitaxel in endometrial ca after platinum + IO (n=776), global study - mOS 19.0 vs 12.1 mos (HR 0.68) - mPFS 7.2 vs 3.9 mos (HR 0.59) - ORR 35.1% vs 17.3% - When available, new option post IO-Chemo 4/5
- Oncology Brothers@OncBrothers
2. MOIO: PhIII, non-inferiority of reduced-frequency (q3mo) vs standard IO in responders with advanced cancer - PFS 25 vs 21.9 mo (HR 1.35) - Death HR 2.0 - No clear safety gain. This is disappointing to see. We need more guidance on who we can de-escalate IO for. 3/5
- Oncology Brothers@OncBrothers
1. ARTEMIS-011: PhIII Ris-Rez (B7-H3 ADC) vs gem/docetaxel in heavily pretreated R/R osteosarcoma (n=122, 🇨🇳 only) - mPFS 5.5 vs 1.4 mos (HR 0.33) - OS trend HR 0.51 (immature) - TEAEs 92.5% vs 83.3% - Need global studies and better management for AEs 2/5
来源：Oncology Brothers · x.com